CACNB2
ENSG00000165995
Target class
Auxiliary transport protein
Chromosome
10
Approved drugs
6
Clinical candidates (approved and in development)
9
- Approved drugs
- 6
- ClinGen gene-disease validity
- Disputed
- Clinical candidates (approved and in development)
- 9
- Chemical probe available
- No
- Target name
- CACNB2
- Gene name
- Calcium voltage-gated channel auxiliary subunit beta 2
- Gene symbol
- CACNB2
- Protein name
- Voltage-dependent L-type calcium channel subunit beta-2 (CAB2) (Calcium channel voltage-dependent subunit beta 2) (Lambert-Eaton myasthenic syndrome antigen B) (MYSB)
- MYSB
- CACNLB2
- Gene biotype
- Protein coding
- Gene family
- Membrane associated guanylate kinases|Calcium voltage-gated channel auxiliary beta subunits
- Target class
- Auxiliary transport protein
- Target type
- Human gene
- Tissues expressed in
- 52
- Highest tissue expression
- 40.3
- Tissue specificity (Gini)
- 0.496
- Tissue specificity (tau)
- 0.796
- KEGG gene identifiers
- hsa:783
- Protein interaction confidence
- 0.822566
- Protein interaction partners
- 53
- R-HSA-112308
- R-HSA-400042
- R-HSA-419037
- R-HSA-422356
- R-HSA-5576892
- R-HSA-5576893
- R-HSA-9662360
- R-HSA-9856532
- End position
- 18543557
- Start position
- 18140424
- Chromosome
- 10
- Strand
- Forward
- Cell membrane, sarcolemma
- Peripheral membrane protein
- Cytoplasmic side .
- Tissue specificity (tau)
- 0.795501
- Expression inequality (Gini)
- 0.495645
Expression in transcripts per million
- Esophagus - Muscularis
- 40.3
- Esophagus - Gastroesophageal Junction
- 35.89
- Brain - Cerebellar Hemisphere
- 27.65
- Pituitary
- 23.96
- Brain - Cerebellum
- 23.26
Expression in transcripts per million
- Esophagus - Muscularis40.3
- Esophagus - Gastroesophageal Junction35.89
- Brain - Cerebellar Hemisphere27.65
- Pituitary23.96
- Brain - Cerebellum23.26
- Bladder21.17
- Colon - Sigmoid20.19
- Brain - Frontal Cortex (BA9)17.7
- Ovary17.35
- Fallopian Tube13.98
- Brain - Cortex13.64
- Uterus13.53
- Cervix - Ectocervix13.4
- Artery - Tibial12.06
- Cervix - Endocervix11.39
- Brain - Anterior cingulate cortex (BA24)11.05
- Small Intestine - Terminal Ileum9.68
- Brain - Nucleus accumbens (basal ganglia)9.36
- Colon - Transverse9.26
- Prostate9.22
- Heart - Atrial Appendage8.75
- Brain - Hypothalamus7.8
- Heart - Left Ventricle7.72
- Artery - Coronary7.7
- Artery - Aorta6.98
And 29 more, listed on the interactive page.
- GO:0007528
- GO:0051928
- GO:0070509
- GO:0086045
- GO:0086091
- GO:0098912
- GO:0005886
- GO:0005891
- GO:1990454
- GO:0005245
- GO:0005515
- GO:0008331
- GO:0086007
- GO:0086056
Related records
Trials (1,011)
- 'Fix the Dysfunction' Concept for Mechanism-based Pharmacological Treatment of Neuropathic Pain by Drug
- [S,S]-Reboxetine Add-On Trial
- 12-Week Efficacy And Safety Of Pregabalin In Treating Restless Legs Syndrome (RLS) Subjects
- 6-Month Open-Label Safety Study Of PD 0332334 In Elderly Patients With Generalized Anxiety Disorder (GAD)
- 600 mg Amoxicillin/42.9 mg Clavulanate Postassium /5 mL Suspension Under Fasting Conditions
- A 10-Week Study Evaluating the Efficacy And Safety of PD 0332334 for the Treatment of Generalized Anxiety Disorder
- A 10-week Study Evaluating the Efficacy and Safety of PD 0332334 for the Treatment of Generalized Anxiety Disorder (3)
- A 10-week Study Evaluating the Efficacy and Safety of PD 0332334 in Patients With Generalized Anxiety Disorder (1)
- A 10-week Study Evaluating the Efficacy and Safety of PD 0332334 in Patients With Generalized Anxiety Disorder (2)
- A 12-Month Study To Evaluate The Safety And Tolerability Of Pregabalin As Add-On Therapy In Pediatric Subjects 1 Month To 16 Years Of Age With Partial Onset Seizures And Pediatric And Adult Subjects 5 To 65 Years Of Age With Primary Generalized Tonic-Clonic Seizures
- A 13-Week, Randomized, Double-Blind, Multicenter, Placebo-Controlled Study Of Pregabalin For Postherpetic Neuralgia
- A 17-Week Trial To Assess Pregabalin For The Treatment Of Nerve Pain Due To Spinal Cord Injury
- A 2-part Study to Assess Local Tolerability, Safety and Pharmacokinetics of Ceftaroline in Healthy Subjects
- A 2-part Trial to Learn More About How BAY1817080 Works, How Safe it is, and What the Right Dose is for Participants With Diabetic Neuropathic Pain
- A 28-Day Polysomnographic Study of Gabapentin in Transient Insomnia Induced by a Sleep Phase Advance
- A 2x2 Factorial, Randomized, Open-label Trial to Evaluate Neuromodulators and Cough Control Therapy in Patients With Refractory or Unexplained Chronic Cough
- A 5-Week Trial Of PD 0332334 And Alprazolam Extended Release Compared To Placebo In Patients With Generalized Anxiety Disorder
- A 52-Week Open-Label Safety Study of PD 0332334 in Subjects With Generalized Anxiety Disorder (GAD)
- A Clinical Study in Subjects With Neuropathic Pain From PHN Who Have Had an Inadequate Response to Gabapentin Treatment
- A Clinical Trial to Compare The Pharmacokinetics of A Pregabalin GLARS Tablet 150mg With Immediate Release Formulation and to Assess The Effect of High Fat Diet in Healthy Male Subjects
Drugs (11)
- Atagabalin Voltage-gated calcium channel modulator
- Bepridil Voltage-gated calcium channel blocker
- Bepridil hydrochloride Voltage-gated calcium channel blocker
- Gabapentin Voltage-gated calcium channel modulator
- Gabapentin enacarbil Voltage-gated calcium channel modulator
- Imagabalin Voltage-gated calcium channel modulator
- Phloroglucinol Voltage-gated calcium channel blocker
- Pregabalin Voltage-gated calcium channel modulator
- Suloctidil Voltage-gated calcium channel blocker
- Terodiline Voltage-gated calcium channel blocker
- Terodiline hydrochloride Voltage-gated calcium channel blocker